HER2 overexpression and/or amplification are mandatorily tested in advanced GC in order to activate a targeted anti-HER2 therapy with trastuzumab and with the antibody–drug conjugate trastuzumab–deruxtecan (T-DXd) [6,56]. Here, ERBB2 is linked to gastric cancer.